eShowcase: ClinPhone Compact
Service Configures Ready-Made Solution for Randomization and Trial Supply Management
Service Configures Ready-Made Solution for Randomization and Trial Supply Management
ClinPhone (Nottingham, UK) announces its ClinPhone Compact, a new service created to meet the needs of many conventional study designs by offering a ready-made application for Interactive Voice Response and Interactive Web Response deployment.
eShowcase: ClinPhone Compact
The new service is hosted by ClinPhone and utilizes its existing infrastructure offerings of 24/7 global support, unlimited language capabilities, and an extensive toll-free network of 82 countries.
ClinPhone Compact allows pharmaceutical and biotechnology sponsors to perform central randomization, emergency code break, medication dispensation, and site and depot supplies management combined with real-time study progress reporting. Because the solution is ready-made, it minimizes the need for study-specific customization, including programming, testing, and validation. As such, this can lower sponsors' costs and accelerate timelines.
ClinPhone plc, +44 (0)115 9557555, www.clinphone.com
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
